Prolonged Response to an IGF-1 Receptor Antibody in a Patient with Metastatic Castration Prostate Cancer with Neuroendocrine Differentiation

The androgen receptor is the main therapeutic target that has been successfully exploited through direct inhibition to extend survival of patients with metastatic castration-resistant prostate cancer (mCRPC). We present a patient who participated in a Phase II study of an antagonist antibody to insu...

Descripción completa

Detalles Bibliográficos
Autores principales: Graff, Julie N, Thomas, George V, Higano, Celestia S, Beer, Tomasz M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2015
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727917/
https://www.ncbi.nlm.nih.gov/pubmed/26848415
http://dx.doi.org/10.7759/cureus.426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727917/
https://www.ncbi.nlm.nih.gov/pubmed/26848415
http://dx.doi.org/10.7759/cureus.426

Ejemplares similares